AU2017249988C1 - Combination therapy with notch and PI3K/mTOR inhibitors for use in treating cancer - Google Patents

Combination therapy with notch and PI3K/mTOR inhibitors for use in treating cancer Download PDF

Info

Publication number
AU2017249988C1
AU2017249988C1 AU2017249988A AU2017249988A AU2017249988C1 AU 2017249988 C1 AU2017249988 C1 AU 2017249988C1 AU 2017249988 A AU2017249988 A AU 2017249988A AU 2017249988 A AU2017249988 A AU 2017249988A AU 2017249988 C1 AU2017249988 C1 AU 2017249988C1
Authority
AU
Australia
Prior art keywords
cancer
acceptable salt
pharmaceutically acceptable
methyl
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017249988A
Other languages
English (en)
Other versions
AU2017249988A1 (en
AU2017249988B2 (en
Inventor
Bharvin Kumar Patel
Michele C. Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2017249988A1 publication Critical patent/AU2017249988A1/en
Application granted granted Critical
Publication of AU2017249988B2 publication Critical patent/AU2017249988B2/en
Publication of AU2017249988C1 publication Critical patent/AU2017249988C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2017249988A 2016-04-12 2017-04-05 Combination therapy with notch and PI3K/mTOR inhibitors for use in treating cancer Active AU2017249988C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662321307P 2016-04-12 2016-04-12
US62/321,307 2016-04-12
PCT/US2017/026099 WO2017180385A1 (en) 2016-04-12 2017-04-05 Combination therapy with notch and pi3k/mtor inhibitors for use in treating cancer

Publications (3)

Publication Number Publication Date
AU2017249988A1 AU2017249988A1 (en) 2018-11-01
AU2017249988B2 AU2017249988B2 (en) 2022-10-27
AU2017249988C1 true AU2017249988C1 (en) 2023-02-16

Family

ID=58548918

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017249988A Active AU2017249988C1 (en) 2016-04-12 2017-04-05 Combination therapy with notch and PI3K/mTOR inhibitors for use in treating cancer

Country Status (11)

Country Link
US (1) US11564929B2 (enExample)
EP (1) EP3442528B1 (enExample)
JP (2) JP6911048B2 (enExample)
KR (1) KR102418766B1 (enExample)
CN (1) CN109310685B (enExample)
AU (1) AU2017249988C1 (enExample)
CA (1) CA3020918A1 (enExample)
ES (1) ES2898952T3 (enExample)
MX (1) MX380780B (enExample)
RU (1) RU2754452C2 (enExample)
WO (1) WO2017180385A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI609687B (zh) 2015-04-14 2018-01-01 美國禮來大藥廠 平滑肌肉瘤之標靶性治療
KR102418765B1 (ko) 2016-04-12 2022-07-08 일라이 릴리 앤드 캄파니 암 치료를 위한 Notch 및 CDK4/6 억제제의 조합 요법
KR102418766B1 (ko) 2016-04-12 2022-07-08 일라이 릴리 앤드 캄파니 암 치료에 사용하기 위한 Notch 및 PI3K/mTOR 억제제의 조합 요법
US10688104B2 (en) 2016-05-20 2020-06-23 Eli Lilly And Company Combination therapy with Notch and PD-1 or PD-L1 inhibitors
EP3525796A1 (en) 2016-10-12 2019-08-21 Eli Lilly and Company Targeted treatment of mature t-cell lymphoma
JP2020507605A (ja) 2017-02-17 2020-03-12 フレッド ハッチンソン キャンサー リサーチ センター Ｂｃｍａ関連癌および自己免疫疾患の治療のための併用療法
MX2020004572A (es) 2017-11-01 2020-10-07 Juno Therapeutics Inc Receptores de antigenos quimericos especificos para el antigeno de maduracion de celulas b y polinucleotidos que codifican los mismos.
EP3706754A1 (en) 2017-11-06 2020-09-16 Juno Therapeutics, Inc. Combination of a cell therapy and a gamma secretase inhibitor
EP4274662A4 (en) * 2021-01-08 2024-11-27 Lantern Pharma Inc. Treatment of brain metastases and cns metastases using illudins or hydroxylureamethyl acylfulvene

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102085372A (zh) * 2009-12-04 2011-06-08 中国医学科学院基础医学研究所 Notch通路抑制剂用于治疗mTOR活化导致的肿瘤的用途
WO2012097039A1 (en) * 2011-01-14 2012-07-19 Eli Lilly And Company Imidazo [4, 5 -c] quinolin- 2 -one compound and its use as pi3 kinase / mtor dual inhibitor
WO2013016081A1 (en) * 2011-07-27 2013-01-31 Eli Lilly And Company Notch pathway signaling inhibitor compound

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR199901343T2 (xx) 1996-12-23 1999-09-21 Elan Pharmaceuticals, Inc. Sikloalkil, laktam, lakton ve ilgili bile�ikler, bunlar� i�eren farmas�tik bile�imler ve b�yle bile�ikler kullan�larak �-amiloid peptidinin sal�nmas�n� ve/veya sentezini inhibe etmek i�in y�ntemler.
WO2000020576A2 (en) 1998-10-02 2000-04-13 The Government Of The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services, The National Institutes Of Health Methods and compositions for inducing differentiation and apotosis in cells that overexpess the notch protein
CA2612241C (en) 2005-07-01 2018-11-06 Medarex, Inc. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
WO2007004743A1 (en) 2005-07-05 2007-01-11 Fujifilm Corporation Copolymer and polymerizable composition
JP4822751B2 (ja) 2005-07-05 2011-11-24 富士フイルム株式会社 共重合体およびその製造方法
US8633179B2 (en) 2007-03-13 2014-01-21 The Trustees Of Columbia University In The City Of New York Synergistic interaction of NOTCH-1 inhibitors with glucocorticoids
SG10201508035TA (en) 2007-03-28 2015-10-29 Pharmacyclics Inc Inhibitors of bruton's tyrosine kinase
CN101778826B (zh) 2007-08-14 2012-10-31 伊莱利利公司 作为γ分泌酶抑制剂的氮杂*衍生物
MA33076B1 (fr) 2008-01-11 2012-03-01 Hoffmann La Roche Utilisation d'un inhibiteur de la gamma-secretase pour le traitement du cancer
PA8852901A1 (es) 2008-12-22 2010-07-27 Lilly Co Eli Inhibidores de proteina cinasa
EP2470054B1 (de) * 2009-08-26 2013-12-04 FrXsh AG Vorrichtung und verfahren zum mischen von mischgut
US8637493B2 (en) 2009-11-12 2014-01-28 University Of Massachusetts Methods for treating glioblastoma
CA2802344C (en) 2010-06-18 2023-06-13 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
JP5737903B2 (ja) 2010-10-26 2015-06-17 三菱重工業株式会社 航空機用配管支持構造
EP2739358B1 (en) 2011-08-01 2018-11-28 F.Hoffmann-La Roche Ag Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
WO2014193898A1 (en) 2013-05-31 2014-12-04 Merck Sharp & Dohme Corp. Combination therapies for cancer
US9827309B2 (en) 2013-08-20 2017-11-28 Merck Sharp & Dohme Corp. Treating cancer with a combination of a PD-1 antagonist and dinaciclib
US10092645B2 (en) 2014-06-17 2018-10-09 Medimmune Limited Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy
WO2016040882A1 (en) 2014-09-13 2016-03-17 Novartis Ag Combination therapies of egfr inhibitors
US20160176962A1 (en) 2014-10-31 2016-06-23 Oncomed Pharmaceuticals, Inc. Combination Therapy For Treatment Of Disease
EP3280795B1 (en) 2015-04-07 2021-03-24 Novartis AG Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
TWI609687B (zh) 2015-04-14 2018-01-01 美國禮來大藥廠 平滑肌肉瘤之標靶性治療
EP3662909A1 (en) 2015-07-24 2020-06-10 Oncotracker, Inc. Gamma secretase modulators for the treatment of immune system dysfunction
KR102418766B1 (ko) 2016-04-12 2022-07-08 일라이 릴리 앤드 캄파니 암 치료에 사용하기 위한 Notch 및 PI3K/mTOR 억제제의 조합 요법
KR102418765B1 (ko) * 2016-04-12 2022-07-08 일라이 릴리 앤드 캄파니 암 치료를 위한 Notch 및 CDK4/6 억제제의 조합 요법
US10688104B2 (en) 2016-05-20 2020-06-23 Eli Lilly And Company Combination therapy with Notch and PD-1 or PD-L1 inhibitors
US20190209581A1 (en) 2016-08-31 2019-07-11 Eli Lilly And Company Dosage regimen for treatment of solid tumors
EP3525796A1 (en) 2016-10-12 2019-08-21 Eli Lilly and Company Targeted treatment of mature t-cell lymphoma
US20200055948A1 (en) 2017-04-28 2020-02-20 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
EP3706754A1 (en) 2017-11-06 2020-09-16 Juno Therapeutics, Inc. Combination of a cell therapy and a gamma secretase inhibitor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102085372A (zh) * 2009-12-04 2011-06-08 中国医学科学院基础医学研究所 Notch通路抑制剂用于治疗mTOR活化导致的肿瘤的用途
WO2012097039A1 (en) * 2011-01-14 2012-07-19 Eli Lilly And Company Imidazo [4, 5 -c] quinolin- 2 -one compound and its use as pi3 kinase / mtor dual inhibitor
WO2013016081A1 (en) * 2011-07-27 2013-01-31 Eli Lilly And Company Notch pathway signaling inhibitor compound

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BENDER, MH "Novel inhibitor of Notch signaling for the treatment of cancer", CANCER RES APRIL 15, 2013 73, XP055277786, Retrieved from the Internet [retrieved on 20211206] *

Also Published As

Publication number Publication date
RU2754452C2 (ru) 2021-09-02
JP7278331B2 (ja) 2023-05-19
EP3442528B1 (en) 2021-05-26
EP3442528A1 (en) 2019-02-20
MX2018012456A (es) 2019-03-07
MX380780B (es) 2025-03-12
KR102418766B1 (ko) 2022-07-08
JP2021169474A (ja) 2021-10-28
KR20180129917A (ko) 2018-12-05
US20210177859A1 (en) 2021-06-17
RU2018138626A (ru) 2020-05-13
CN109310685A (zh) 2019-02-05
CA3020918A1 (en) 2017-10-19
WO2017180385A1 (en) 2017-10-19
RU2018138626A3 (enExample) 2020-09-21
JP2019511529A (ja) 2019-04-25
JP6911048B2 (ja) 2021-07-28
AU2017249988A1 (en) 2018-11-01
US11564929B2 (en) 2023-01-31
ES2898952T3 (es) 2022-03-09
AU2017249988B2 (en) 2022-10-27
CN109310685B (zh) 2021-10-29

Similar Documents

Publication Publication Date Title
AU2017249988B2 (en) Combination therapy with notch and PI3K/mTOR inhibitors for use in treating cancer
AU2017249078B2 (en) Combination therapy with notch and CDK4/6 inhibitors for the treatment of cancer
ES3064856T3 (en) Combinations of irs/stat3 dual modulators and anti-cancer agents for treating cancer
AU2015360095A1 (en) Quinoline derivative against non-small cell lung cancer
CN107427522A (zh) 用于治疗黑素瘤的阿吡莫德
KR20140040728A (ko) Pi3k 억제제 화합물을 사용한 중피종 치료 방법
KR20230008719A (ko) Tno155 및 나자르티닙을 포함하는 약제학적 조합물
HK40004471B (en) Combination therapy with notch and pi3k/mtor inhibitors for use in treating ovarian cancer
HK40004471A (en) Combination therapy with notch and pi3k/mtor inhibitors for use in treating ovarian cancer
NZ786609A (en) Combination therapy with notch and pi3k/mtor inhibitors for use in treating cancer
HK40004472B (en) Combination therapy with notch and cdk4/6 inhibitors for the treatment of lung cancer
HK40004472A (en) Combination therapy with notch and cdk4/6 inhibitors for the treatment of lung cancer
NZ786604A (en) Combination therapy with notch and cdk4/6 inhibitors for the treatment of
WO2025049904A1 (en) Egfr inhibitor for use in the treatment of lung cancer positive for an egfr exon 20 mutation
NZ788180A (en) Combination therapy with notch and pd-1 or pd-l1 inhibitors

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 04 NOV 2022

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 04 NOV 2022

FGA Letters patent sealed or granted (standard patent)